Aptose Biosciences Inc. APTO
We take great care to ensure that the data presented and summarized in this overview for Aptose Biosciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APTO
Top Purchases
Top Sells
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Insider Transactions at APTO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+14.02%
|
$0
$0.2 P/Share
|
|
Sep 22
2023
|
Bernd R. Seizinger |
BUY
Open market or private purchase
|
Direct |
17,000
+50.0%
|
$51,000
$3.14 P/Share
|
|
Jan 19
2023
|
William G. Rice Chair, President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+22.62%
|
-
|
|
Jan 19
2023
|
Philippe Ledru |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+49.88%
|
-
|
|
Jan 19
2023
|
Fletcher Payne Sr VP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jan 19
2023
|
Rafael Bejar Sr VP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+47.62%
|
-
|
|
Sep 19
2022
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+2.68%
|
$0
$0.68 P/Share
|
|
Sep 19
2022
|
Fletcher Payne Sr VP and CFO |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$0
$0.68 P/Share
|
|
Jun 06
2022
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+2.75%
|
$0
$0.97 P/Share
|
|
Dec 20
2021
|
Denis R Burger |
BUY
Open market or private purchase
|
Direct |
10,000
+24.0%
|
$10,000
$1.45 P/Share
|
|
Dec 16
2021
|
Erich Platzer |
BUY
Open market or private purchase
|
Direct |
100,000
+6.51%
|
$100,000
$1.38 P/Share
|
|
Dec 16
2021
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
13,183
+3.7%
|
$13,183
$1.52 P/Share
|
|
Dec 15
2021
|
Erich Platzer |
BUY
Open market or private purchase
|
Direct |
270,000
+16.88%
|
$270,000
$1.18 P/Share
|
|
Dec 15
2021
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
17,822
+5.12%
|
$17,822
$1.12 P/Share
|
|
Nov 26
2021
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
8,643
+2.69%
|
$17,286
$2.31 P/Share
|
|
Nov 19
2021
|
Rafael Bejar Sr VP & Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$20,000
$2.56 P/Share
|
|
Nov 19
2021
|
Denis R Burger |
BUY
Exercise of conversion of derivative security
|
Direct |
5,417
+20.0%
|
$10,834
$2.04 P/Share
|
|
Aug 05
2021
|
Donald R. Wilson Jr. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
60,000
-0.67%
|
$120,000
$2.62 P/Share
|
|
Aug 03
2021
|
Donald R. Wilson Jr. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
57,199
+0.64%
|
$114,398
$2.65 P/Share
|
|
Jul 02
2021
|
William G. Rice Chair, President & CEO |
BUY
Open market or private purchase
|
Direct |
6,081
+1.96%
|
$18,243
$3.29 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 100K shares |
|---|